Tomorrow's Cell
Therapies, Today®

Pluristyx provides the expertise and tools

to support and accelerate the development and commercialization of revolutionary therapeutics.

We Simplify the Stem Cell Therapy

Development Process

Derivation
Gene Editing
Product
Banking
Expansion

We Simplify the Stem Cell Therapy

Development Process

Derivation
Gene Editing
Product
Banking
Expansion

Why Pluristyx, powered by panCELLa?

Through the panCELLa platform, Pluristyx provides the expertise and tools to support and accelerate the development and commercialization of revolutionary therapeutics.

End-to-End Solutions

With our enlarged portfolio of unique non-modified and genetically engineered iPSC-based technologies, we can assist you at any stage in your product development workflow.

Gene Edits

Offering an array of gene editing technologies resulting in unparalleled functional control of commercial products.

Clinical Path iPSC

Leading provider of gene-edited iPSC and cell therapy solutions, accelerating the path to clinic and providing the best route to commercialization. 

Scientific Expertise

Veteran expertise from industry leaders in the field of stem cell biology developmental genetics and cell therapy.   

End-to-End Solutions

With our enlarged portfolio of unique non-modified and genetically engineered iPSC-based technologies, we can assist you at any stage in your product development workflow.

Gene Edits

Offering an array of gene editing technologies resulting in unparalleled functional control of commercial products.

Clinical Path iPSC

Leading provider of gene-edited iPSC and cell therapy solutions, accelerating the path to clinic and providing the best route to commercialization. 

Scientific Expertise

We have over 50 years of executive experience in development and manufacturing.  

Try Before You Buy

Would you like to experience our technology firsthand before committing to a license agreement We welcome you to have access to our various product offerings before you purchase a commercial license. 

Your Problems,
Our Solutions

To overcome any obstacle you’re facing, panCELLa, a novel platform for rapid, efficacious, and high-quality iPSC therapy development, can turn your bold ideas into reality.  

Your Problems, Our Solutions

To overcome any obstacle you’re facing, panCELLa, a novel platform for rapid, efficacious, and high-quality iPSC therapy development, can turn your bold ideas into reality.  

About Pluristyx​

Pluristyx, powered by panCELLa offers an enlarged portfolio of unique and effective non-modified and genetically engineered iPSC-based technologies and related services to provide end-to-end client support throughout the product lifecycle.  

About Pluristyx​

Pluristyx powered by panCELLa offers an enlarged portfolio of unique and effective non-modified and genetically engineered iPSC-based technologies and related services to provide end-to-end client support throughout the product lifecycle.  

About Pluristyx​

Pluristyx powered by panCELLa offers an enlarged portfolio of unique and effective non-modified and genetically engineered iPSC-based technologies and related services to provide end-to-end client support throughout the product lifecycle.  

Latest News​

Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells

The addition of ES cells and iPSCs will enhance Charles River’s portfolio of powerful research tools supporting acceleration of therapeutic development. WILMINGTON, Mass. – February 20, 2024 – Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered...

Pluristyx and Resilience Form Partnership to Accelerate the Development of Promising Stem Cell Therapies

Pluristyx, Inc., with expertise in gene-edited induced pluripotent stem cells (iPSCs) and National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines today, today announced a collaboration agreement to streamline the transition of promising iPSC-derived...

Pluristyx Announces Major New Funding Round to Bolster Expansion Plans

SEATTLE, WA - December 21, 2023 - Pluristyx, a leading provider of tools, technologies and services for the development of cell therapies, has today announced the closing of a major fundraising round led by BroadOak Capital Partners. The oversubscribed funding...

Shopping Cart
Scroll to Top